Stada Arzneimittel’s (STDAF) “Sell” Rating Reaffirmed at DZ Bank

DZ Bank reaffirmed their sell rating on shares of Stada Arzneimittel (OTCMKTS:STDAF) in a research note issued to investors on Wednesday.

Stada Arzneimittel (OTCMKTS:STDAF) remained flat at $$100.50 during mid-day trading on Wednesday. Stada Arzneimittel has a 52 week low of $51.40 and a 52 week high of $100.50. The company has a market capitalization of $6,265.37, a P/E ratio of 29.73 and a beta of -1.73.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at

Stada Arzneimittel Company Profile

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit